Paradoxical HDL‐C reduction during rosiglitazone and fibrate treatment

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Diabetic Medicine

• Publication date

  2007-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1464-5491.2007.02029.xPMID 17227331
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of Angiotensin Converting Enzyme Inhibition in Patients With Stable Coronary Artery Disease: The Prevention of Events With Angiotensin Converting Enzyme Inhibition (PEACE) Trial: The PEACE Study Investigators

  2005cited by this paper
• A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.

  2005cited by this paper
• Severe hypo-alpha-lipoproteinemia during treatment with rosiglitazone.

  2004cited by this paper
• Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol.

  2004cited by this paper
• Severe Hypo-α-Lipoproteinemia During Treatment With Rosiglitazone

  2004cited by this paper
• Thiazolidinediones: comparison of long-term effects on glycemic control and cardiovascular risk factors

  2004cited by this paper
• A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.

  2004cited by this paper
• Paradoxical lowering of high-density lipoprotein cholesterol level in 2 patients receiving fenofibrate and a thiazolidinedione.

  2003cited by this paper
• Paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate: reply by the authors

  2002cited by this paper
• Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records.

  2002cited by this paper
• Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus.

  2002cited by this paper
• Differentiating members of the thiazolidinedione class: a focus on efficacy

  2002cited by this paper
• Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice.

  2001cited by this paper
• The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes

  1999cited by this paper
• Metabolism of Apolipoproteins AI and AII in a Patient with Paradoxical Reduction in High-Density Lipoprotein Due to Ciprofibrate

  1999cited by this paper
• Mechanism of action of fibrates on lipid and lipoprotein metabolism.

  1998cited by this paper
• Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23)

  1998cited by this paper
• Paradoxical High-Density Lipoprotein Reduction Induced by Fenofibrate and Ciprofibrate

  1996cited by this paper

• Use of fibrates in the metabolic syndrome: A review.

  2016cites this paper
• Diabetes education: a global perspective

  2015cites this paper
• Metabolic syndrome: A review of the role of vitamin D in mediating susceptibility and outcome.

  2015cites this paper
• Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone*

  2015cites this paper
• Fibrates: From PPARα activation to clinical use in the metabolic syndrome

  2015cites this paper
• Treatment of metabolic syndrome with ankaflavin, a secondary metabolite isolated from the edible fungus Monascus spp.

  2014cites this paper
• Paradoxical Reduction in HDL-C With Fenofibrate and Thiazolidinedione Therapy in Type 2 Diabetes: The ACCORD Lipid Trial

  2014cites this paper
• The improvements of ankaflavin isolated from Monascus-fermented products on dyslipidemia in high-fat diet-induced hasmster

  2013cites this paper
• Amorfrutin B is an efficient natural peroxisome proliferator-activated receptor gamma (PPARγ) agonist with potent glucose-lowering properties

  2013cites this paper
• Diabetes education: what do adolescents want?

  2012cites this paper
• Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes

  2011cites this paper
• Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin

  2011cites this paper
• Combination of fenofibrate with non-statin drug regimens.

  2010cites this paper
• Paradoxical severe decrease in high-density lipoprotein cholesterol due to rosiglitazone-fenofibrate interaction.

  2010cites this paper
• [HDL cholesterol reduction during rosiglitazone and fenofibrate treatment in a type 2 diabetes mellitus patient with dyslipidemia].

  2010influential citation
• Severe HDL-c reduction during rosiglitazone therapy in an obese woman with type 2 diabetes.

  2010cites this paper
• Severe HDLc reduction during rosiglitazone therapy in an obese woman with type 2 diabetes

  2010influential citation
• PARADOxICAl S EVERE DECREASE IN HIgH-DENSITy lIPOPROTEIN CHOl ESTEROl Du E TO ROSIgl ITAz ONE-FENOFIbRATE INTERACTION

  2010cites this paper
• [Drug therapy of type 2 diabetes and cardiovascular prevention: potentials for liraglutide].

  2009cites this paper
• Paradoxical decreases in high-density lipoprotein cholesterol with fenofibrate: a quite common phenomenon

  2009cites this paper
• Iatrogenic Severe Depression of High‐Density Lipoprotein Cholesterol

  2009cites this paper
• Paradoxical fall in HDL cholesterol observed in a patient treated with rosiglitazone and pioglitazone

  2009cites this paper
• Il trattamento farmacologico del diabete di tipo 2 e la prevenzione cardiovascolare: cosa aggiunge liraglutide?

  2009cites this paper
• How safe is the use of thiazolidinediones in clinical practice?

  2009cites this paper
• Bibliography. Current world literature. Diabetes and the endocrine pancreas.

  2008cites this paper
• Combination thiazolidinedione and fibrate effect on high-density lipoprotein cholesterol (HDL-C) concentration in a Veterans Affairs patient population.

  2008cites this paper
• Reduced high-density lipoprotein cholesterol in patients receiving rosiglitazone and fenofibrate.

  2008cites this paper
• Current literature in diabetes

  2007cites this paper
• Weight No More: a randomised controlled trial for people with type 2 diabetes on insulin therapy

  2007cites this paper
• Paradoxical decrease in high density lipoprotein-cholesterol associated with statin and fenofibrate combination therapy:

  2007cites this paper